89 related articles for article (PubMed ID: 22204455)
21. [A clinical study of treating 120 cases of adult chronic myelocytic leukemia with imatinib mesylate].
Chen ZC; You Y; Zhu XM; Li QB; Li WM; Zou P
Zhonghua Nei Ke Za Zhi; 2007 Dec; 46(12):1003-6. PubMed ID: 18478917
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR
Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
[TBL] [Abstract][Full Text] [Related]
23. Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results.
Palandri F; Testoni N; Luatti S; Marzocchi G; Baldazzi C; Stacchini M; Castagnetti F; Breccia M; Specchia G; Pane F; Saglio G; Martinelli G; Baccarani M; Rosti G
Leuk Lymphoma; 2009 Jan; 50(1):114-8. PubMed ID: 19125382
[No Abstract] [Full Text] [Related]
24. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
[TBL] [Abstract][Full Text] [Related]
25. Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia.
Ross DM; Jackson SR; Browett PJ
Leuk Lymphoma; 2007 Jun; 48(6):1231-3. PubMed ID: 17577792
[No Abstract] [Full Text] [Related]
26. Initial treatment for patients with CML.
Goldman JM
Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
[TBL] [Abstract][Full Text] [Related]
27. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.
Neelakantan P; Gerrard G; Lucas C; Milojkovic D; May P; Wang L; Paliompeis C; Bua M; Reid A; Rezvani K; O'Brien S; Clark R; Goldman J; Marin D
Blood; 2013 Apr; 121(14):2739-42. PubMed ID: 23380743
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study.
Bengió RM; Riva ME; Moiraghi B; Lanari E; Milone J; Ventriglia V; Bullorsky E; Tezanos Pinto Md; Murro H; Bianchini M; Larripa I
Leuk Lymphoma; 2011 Sep; 52(9):1720-6. PubMed ID: 21663510
[TBL] [Abstract][Full Text] [Related]
29. Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?
Marin D; Khorashad JS; Foroni L; Milojkovic D; Szydlo R; Reid AG; Rezvani K; Bua M; Goldman JM; Apperley JF
Br J Haematol; 2009 May; 145(3):373-5. PubMed ID: 19344397
[TBL] [Abstract][Full Text] [Related]
30. Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia.
Guillem V; Amat P; Cervantes F; Alvarez-Larrán A; Cervera J; Maffioli M; Bellosillo B; Collado M; Marugán I; Martínez-Ruiz F; Hernández-Boluda JC
Leuk Res; 2012 Feb; 36(2):174-81. PubMed ID: 21724255
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous occurrence of a t(9;22) (Ph) with a t(2;11) in a patient with CML and emergence of a new clone with the t(2;11) alone after imatinib mesylate treatment.
Royer-Pokora B; Hildebrandt B; Redmann A; Herold C; Kronenwett R; Haas R; Drechsler M; Wieland C
Leukemia; 2003 Apr; 17(4):807-10. PubMed ID: 12682644
[No Abstract] [Full Text] [Related]
32. Profile of BCR-ABL transcript levels based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib.
Ashariati A; Ugroseno S
Acta Med Indones; 2013 Apr; 45(2):107-13. PubMed ID: 23770790
[TBL] [Abstract][Full Text] [Related]
33. [Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study].
Berger U; Hehlmann R
Internist (Berl); 2004 Jan; 45(1):102-3. PubMed ID: 14735248
[No Abstract] [Full Text] [Related]
34. Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response.
White DL; Hughes TP
J Clin Oncol; 2012 Apr; 30(10):1144-5; author reply 1145-6. PubMed ID: 22393079
[No Abstract] [Full Text] [Related]
35. High
Vigneri P; Stagno F; Stella S; Cupri A; Forte S; Massimino M; Antolino A; Siragusa S; Mannina D; Impera SS; Musolino C; Malato A; Mineo G; Tomaselli C; Murgano P; Musso M; Morabito F; Molica S; Martino B; Manzella L; Müller MC; Hochhaus A; Raimondo FD
Clin Cancer Res; 2017 Dec; 23(23):7189-7198. PubMed ID: 28928163
[No Abstract] [Full Text] [Related]
36. Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib.
Chahardouli B; Zaker F; Mousavi SA; Saffari Z; Nadali F; Ostadali M; Ghadimi H; Alimoghaddam K; Ghavamzade A; Rostami S
Hematology; 2013 Nov; 18(6):328-33. PubMed ID: 23676790
[TBL] [Abstract][Full Text] [Related]
37. Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia.
Kong JH; Mun YC; Kim S; Choi HS; Kim YK; Kim HJ; Moon JH; Sohn SK; Kim SH; Jung CW; Dennis Kim DH
Int J Hematol; 2012 Sep; 96(3):327-33. PubMed ID: 22821389
[TBL] [Abstract][Full Text] [Related]
38. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
Murai K; Akagi T; Shimosegawa K; Sugawara T; Ishizawa K; Ito S; Murai K; Motegi M; Yokoyama H; Noji H; Tajima K; Kimura J; Chou T; Ogawa K; Harigae H; Kubo K; Oba K; Sakamoto J; Ishida Y
Eur J Haematol; 2015 Dec; 95(6):558-65. PubMed ID: 25703064
[TBL] [Abstract][Full Text] [Related]
39. Mutations in ABL kinase domain are associated with inferior progression-free survival.
Sharma P; Mohanty S; Kochupillai V; Kumar L
Leuk Lymphoma; 2010 Jun; 51(6):1072-8. PubMed ID: 20367437
[TBL] [Abstract][Full Text] [Related]
40. Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response.
Agirre X; Fontalba A; Andreu EJ; Odero MD; Larráyoz MJ; Montiel C; Calasanz MJ; Fernández-Luna JL; Prósper F
Haematologica; 2003 Dec; 88(12):1425-6. PubMed ID: 14687999
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
